Clinical trials, biomarkers, microbiome, genetics, AI, basic science, and emerging IBD research.
Page 43 of 66 · 3121 articles
This trial directly informs a common clinical question: whether patients in deep remission can safely stop anti‑TNF therapy. Results show higher relapse risk after withdrawal, but many patients can be successfully...
This study describes a new plant-derived nanoparticle (EBDEVs) that reduced inflammation and improved colon health in a mouse model of ulcerative colitis and altered the gut microbiota — early evidence that may guide...
The study proposes a targeted oral delivery method that could help concentrate anti-inflammatory natural compounds at inflamed colon sites, potentially improving treatment effectiveness for ulcerative colitis while...
Antibiotics commonly used against anaerobes affected opportunistic IBD-associated strains and beneficial commensals differently in lab cultures; this could influence thinking about using broad‑spectrum antibiotics to...
A new Phase 2 trial is testing whether intravenous allogeneic HB-adMSCs can improve Crohn’s symptoms and intestinal inflammation. If effective and safe, the therapy could offer a different mechanism of treatment from...
A new investigational drug (BI 3032950) is being tested specifically for people with ulcerative colitis who did not do well on prior biologic or targeted treatments. If effective and safe, it could become another option...
Patients on anti-TNF biologics often seek safe ways to support gut microbial health. This trial tests a prebiotic supplement (2'-FL) for safety and whether it increases beneficial bacteria and butyrate in young people...
People with Crohn’s disease who are overweight or have obesity may have different disease and treatment needs. This Phase 3 trial is testing whether adding tirzepatide to mirikizumab improves both disease outcomes and...
The study reports a novel nanoparticle method to deliver curcumin specifically to inflamed colon tissue, which in mice improved gut inflammation, microbiome balance, barrier repair, and depression‑like behaviors—areas...
A genetic marker (HLA-DRB1*01:03) was linked to more severe IBD outcomes—higher rates of colectomy/colonic surgery, more perianal disease, earlier use and higher failure of advanced therapies—which could help explain...
This work describes a novel engineered probiotic designed to survive the gastrointestinal tract and act specifically at inflamed colitis sites, which could lead to new targeted therapies for IBD if validated in humans.
People with Crohn’s disease on ustekinumab may be more likely to need intensified dosing if they previously tried biologics or immunomodulators or have had disease longer; this could affect monitoring and planning. For...
Adolescents with IBD often experience abdominal pain that affects daily life. This study suggests psychological resilience — especially optimism and mindfulness — is linked with less pain, pointing to nonpharmacologic...
The study suggests people with Crohn's disease or ulcerative colitis have higher lipoprotein(a) levels than healthy controls, which could be relevant because Lp(a) is a cardiovascular-risk biomarker and cardiovascular...
IOIBD’s consensus frameworks and educational programs shape how IBD is studied and treated worldwide — affecting trial design, treatment goals, patient-reported outcome measures, and clinical guidance that patients and...
A probe that images superoxide in inflamed colons could help researchers study oxidative stress in ulcerative colitis and potentially guide development of new biomarkers or imaging approaches.
This study highlights that people who go on to develop myasthenia gravis had higher rates of other autoimmune diagnoses in the years beforehand, which may be relevant for clinicians tracking autoimmune comorbidity...
If approved, a vedolizumab biosimilar could increase treatment options and competitive pricing for adults with moderate-to-severe ulcerative colitis or Crohn's disease. The company already markets a natalizumab...
If you are Ashkenazi Jewish or care for someone who is, research shows higher group-level risk for Crohn’s disease, ulcerative colitis and lactose intolerance—so awareness and early evaluation for gut symptoms may be...
The study suggests a combined probiotic-plus-nutrient approach may improve intestinal barrier integrity, reduce inflammation, and restore epithelial metabolism in an IBD model—areas not fully addressed by current...
Researchers tested a ginger-derived glucan that reduced inflammation and reshaped the gut microbiota in a mouse colitis model — a potential prebiotic approach that could inform future IBD therapies or dietary strategies.
This paper suggests that epithelial barrier structure and function may be altered in very early onset pediatric IBD. That could help researchers study disease mechanisms and eventually guide targeted therapies for...
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
The review links macrophage-driven repair mechanisms to chronic inflammation and fibrosis in autoimmune diseases, including IBD, and highlights experimental strategies that aim to promote resolution rather than suppress...
The microbiome is increasingly viewed as an influence on IBD development and persistence, and microbiome-directed therapies (like FMT and engineered bacteria) are an active area of research that could one day add to...
This study reports a new colon-targeted delivery system for unconjugated bilirubin that reduced inflammation and improved mucosal healing in a mouse model of ulcerative colitis; it could inform future drug-development...
This study expands knowledge of UC genetics in an understudied Indian population and points to genes and pathways that could help explain disease mechanisms different from those identified in Western cohorts. That could...
Based on the title and source metadata, this appears to be a basic science related to Inflammatory bowel disease and Research and clinical trials. The original article is from International Immunopharmacology.
Phase 1 platform studies like this one test safety and tolerability of new treatments for moderate-to-severe ulcerative colitis before larger trials. Findings from such early studies determine whether a drug moves...
People with moderate-to-severe Crohn's disease or ulcerative colitis and their clinicians may want to know how long patients stay on guselkumab in real-world care, since persistence reflects tolerability, benefit, and...
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
This study evaluated whether blood levels of LRG track endoscopic and clinical disease activity in people with suspected UC or Crohn’s disease, which could point to a noninvasive inflammation biomarker.
Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.
Surgical approach to creating an IPAA (j-pouch) affects timing and number of operations and recovery; trends toward more staged procedures may reflect increasing disease severity and preoperative treatment patterns that...
Dual-energy CT quantification of creeping fat could offer a measurable imaging biomarker that reflects transmural inflammation and fibrosis in Crohn’s disease, potentially improving monitoring beyond mucosal healing.
The work narrows down which genes are likely influenced by Crohn’s disease–associated regulatory DNA in a specific gut immune cell type, helping researchers prioritize targets and understand disease mechanisms.
IBD is linked with mood and cognitive symptoms via systemic and gut‑brain inflammation, so preclinical findings that a cashew kernel extract reduced inflammation and behavioral changes could point to new research...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
Depression is common in people with ulcerative colitis and affects quality of life and disease outcomes. Knowing research trends helps patients and clinicians see where evidence and care approaches are focused,...
Finding shared genes (CLDN8, ABCA12) suggests common inflammatory mechanisms between ulcerative colitis and psoriasis, which could inform future biomarkers or therapies relevant to patients with either or both...
The study shows a probiotic strain reduced inflammation and improved gut barrier and microbiome/metabolite profiles in a mouse colitis model, indicating a possible new avenue for UC therapies worth further research.
Cure8 found this source from Gastroenterology, but the page could not be read reliably yet. It is tagged for Inflammatory bowel disease and Research and clinical trials. Open the original article for the full details.
This study helps distinguish patterns of colorectal dysplasia seen in people without IBD from those seen in IBD, which may affect how pathologists and clinicians interpret biopsy findings and consider cancer risk and...
This study identifies a plant-derived compound that reduced inflammation and promoted intestinal healing in mouse models by modulating the Wnt/β-catenin pathway and ILC3-driven IL-22 production—pathways relevant to...
XOR is linked to oxidative stress, inflammation, drug (thiopurine) metabolism, microbiome interactions, and inflammation-associated colorectal cancer — all processes relevant to IBD pathogenesis and complications....
People with IBD already face higher cardiovascular risk; drugs used to treat IBD (anti-TNF and JAK inhibitors) may differently affect small-vessel endothelial function, a possible contributor to heart and vascular...
The study links patient-specific non-coding genetic variation to epithelial regulatory networks and to differences in disease severity and response in a large UC trial, suggesting genetics could help explain why some...
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Research and clinical trials. The original article is from Journal of...
